ABC | Volume 112, Nº6, Junho 2019

Artigo Original Rajão et al Disfunção tireoidiana subclínica e arritmias Arq Bras Cardiol. 2019; 112(6):758-766 1. Vanderpump M, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol. 1995;43(1):55-68. 2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526-34. 3. Donangelo I, BraunsteinG. Update on subclinical hyperthyroidism. AmFam Physician. 2011;83(8):933-8. 4. Benseñor IM, Goulart AC, Lotufo PA, Menezes PR, ScazufcaM. Prevalence of thyroid disorders among older people: results from the São Paulo Ageing & Health Study. Cad Saude Publica. 2011;27(1):155-61. 5. Sgarbi JA, Matsumura LK, Kasamatsu TS, Ferreira SR, Maciel RM. STDs are independent risk factors for mortality in a 7.5-year follow-up: the Japanese- Brasilian thyroid study. Eur J Endocrinol. 2010;162(3):569-77. 6. Sichieri R, Baima J, Marante T, de Vasconcellos MT, Moura AS, Vaisman M. Low prevalence of hypothyroidism among black and Mulatto people in a population-based study of Brazilian women. Clin Endocrinol. 2007;66(6):803-7. 7. Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, et al. Subclinical and overt thyroid dysfunction and risk of all- cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014;99(7):2372-82. 8. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, et al. Meta- analysis: Subclinical Thyroid Disfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148(11):832-45. 9. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295(9):1033-41. 10. Waring AC, Arnold AM, Newman AB, Bùzkova P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012;97(11):3944-50. 11. Kaminski G, Makowski K, MichałkiewiczD, Kowal J, RuchalaM, Szczepanek E,etal.The influenceofsubclinicalhyperthyroidismonbloodpressure,heart rate variability, and prevalence of arrhythmias. Thyroid. 2012;22(5):454-60. 12. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249-52. 13. BiondiB,PalmieriEA,FazioS,CoscoC,NoceraM,SaccàL,etal.Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85(12):4701-5. 14. Petretta M, Bonaduce D, Spinelli L, Vicario ML, Nuzzo V, Marciano F, et al. Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145(6):691-6. 15. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142(5):838-42. 16. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928-34. 17. Vadiveloo T, Donnan P, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96(5):1344-51. 18. Owecki M, Michalak A, Nikisch E, Sowinski J. Prolonged ventricular repolarization measured by corrected QT interval (QTc) in subclinical hyperthyroidism. HormMetab Res. 2006;38(1):44-7. 19. Biondi B, Palmieri E, Lombardi G, Fazio S. Subclinical hypothyroidism and cardiac function. Thyroid. 2002;12(6):505-10. 20. Sarma JS, Venkataraman K, Nicod P, Polikar R, Smith J, SchoenbaumMP, et al. Circadian Rhythmicity of rate-normalizedQT interval in hypothyroidism and its significance for development of class III antiarrhythmic agents. Am J Cardiol. 1990;66(12):959-63. 21. Aquino EM, Barreto SM, Benseñor IM, Carvalho MS, Chor D, Duncan BB, et al. Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): objectives and design. Am J Epidemiol. 2012;175(4):315-24. 22. Kailajärvi M, Takala T, Grönros P, Tryding N, Viikari J, Irjala K, et al. Reminders of drug effects on laboratory tests results. Clin Chem. 2000;46(9):1395-400. 23. Mill JG, Pinto K, Griep RH, Goulart A, Foppa M, Lotufo PA, et al. Medical assessments and measurements in ELSA-Brasil. Rev Saude Publica. 2013;47(Suppl 2):54-62. 24. Prineas RJ, Crow RS, Blackburn HW. The Minnesota Code Manual of Electrocardiographic Findings: standards and procedures for measurement and classification. Boston, MA: John Wright; 1982. 25. Fedeli LG, Vidigal PG, Leite CM, Castilhos CD, Pimentel RA, Maniero VC, et al. Logistics of collection and transportation of biological samples and the organization of the central laboratory in the ELSA-Brasil. Rev Saude Publica. 2013;47(Suppl 2):63-71. 26. Pinto- Filho MM, Brant LCC, Padilha-da-Silva JL, Foppa M, Lotufo PA, Mill JG, et al. Electrocardiographic Findings in Brazilian Adults without Heart Disease: ELSA-Brasil. Arq Bras Cardiol. 2017;109(5):416-24. 27. Haugen BR. Drugs that suppress TSHor cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23(6):793-800. 28. Carvalho GA, Perez CLS, Ward LS. The clinical use of thyroid function tests. Arq Bras Endocrinol Metab. 2013;57(3):193-204. Referências Aprovação ética e consentimento informado Este estudo foi aprovado pelo Comitê de Ética da Universidade Federal de Minas Gerais sob o número de protocolo ETIC 186/06. Todos os procedimentos envolvidos nesse estudo estão de acordo com a Declaração de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes incluídos no estudo. 765